This week Berwick Partners hosted its first life sciences industry event in central London, the first of many to come! The evening was a great success and attended by a variety of life science industry leaders. We were delighted to welcome Dr Ian Hudson, CEO of the Medicines and Healthcare Regulatory Agency (MHRA) as our guest speaker.
The main themes discussed were innovation in the life sciences industry, the constant need for new medicines and devices, and the barriers the industry faces to this. Ian shared insight into the MHRA and the key areas in which they operate including the Accelerated Access Review. Through this MHRA can assist innovators with speeding up the adoption process, helping patients gain early access to vital drugs, particularly those with high unmet medical need.
Ian also touched upon the current landscape in the EU market as Brexit negotiations take place in parliament. MHRA’s current positon is business as usual, with no major changes or upheavals in UK medicine and device regulation. It is also clear, and quite important to mention, that MHRA is one of the world’s key regulatory offices that plays a vital role in drug and device regulation in the EU. MHRA provides 35% of regulatory approvals in other European countries and is an important and key location for medical innovation. One concern that was raised during the evening involved the European Medicines Agency’s plan to leave the UK after Brexit, creating uncertainty for UK-based pharmaceutical firms about the regulatory regime for drugs in future.
We would like to thank all who attended the event, and particularly Ian for providing interesting thoughts and insight, contributing to a thoroughly enjoyable evening.
Berwick Partners’ Life Sciences Practice takes a keen interest in developments and news in the sector and would love to hear from you if you have comments to share. Likewise if you are interested in our future events please get in touch.